Abselion has expanded its product offering with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit, designed for use with its Amperia benchtop quantification platform.

The kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents, providing enhanced specificity, consistency, and reduced need for in-house optimisation. They enable researchers working in adeno-associated virus (AAV) development and characterisation to generate reproducible titre measurements across a broad range of serotypes and process conditions.

The Amperia platform offers rapid, automated quantification of biomolecules without optics, fluidics or specialist training. Each kit comes ready-to-use with sensor strips, assay plates, matched detection reagents and assay buffers. This expanded kit range simplifies total capsid quantification from purified or complex samples, supporting gene therapy development and process workflows.

Abselion has licensed CaptureSelect reagents from Thermo Fisher Scientific, which use recombinant single-domain antibodies for high target specificity, low cross-reactivity and consistent batch performance. The integration of these reagents enhances the assay format and broadens serotype applicability.

Both kits employ a sandwich-style immunoassay, where biotin- and HRP-conjugated CaptureSelect antibodies sequentially bind AAV capsids. Detection is electrochemical using Amperia sensor strips, allowing accurate quantification across diverse AAV samples and concentrations.

The AAVX kit covers AAV1–8 and AAVrh10, while the AAV9 kit focuses specifically on AAV9 particles.

Dr Ruizhi Wang, CEO and founder of Abselion, said: “Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible. With these additions, Amperia offers researchers a ready-to-use solution that combines trusted reagent technologies with a streamlined assay format, enabling reliable quantification across a wider range of serotypes and development workflows.”

Dr Kelly Flook, senior manager, product management, pharma analytics at Thermo Fisher Scientific, added: “CaptureSelect affinity reagents are designed to deliver high specificity and lot-to-lot consistency, making them well suited for applications such as AAV capsid quantification. We’re pleased that Abselion has incorporated these reagents under licence to support their assay kits for the Amperia platform.”